IS6425A - Nýir sertralínhýdróklóríð fjölgervingar, aðferðirtil að búa þá til, blöndur sem innihalda þá og aðferðir til að nota þá - Google Patents

Nýir sertralínhýdróklóríð fjölgervingar, aðferðirtil að búa þá til, blöndur sem innihalda þá og aðferðir til að nota þá

Info

Publication number
IS6425A
IS6425A IS6425A IS6425A IS6425A IS 6425 A IS6425 A IS 6425A IS 6425 A IS6425 A IS 6425A IS 6425 A IS6425 A IS 6425A IS 6425 A IS6425 A IS 6425A
Authority
IS
Iceland
Prior art keywords
methods
sertraline hydrochloride
polyphenols
making
new
Prior art date
Application number
IS6425A
Other languages
English (en)
Inventor
Aronhime Judith
Mendelovici Marioana
Nidam Tamar
Singer Claude
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of IS6425A publication Critical patent/IS6425A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IS6425A 1999-12-21 2002-06-18 Nýir sertralínhýdróklóríð fjölgervingar, aðferðirtil að búa þá til, blöndur sem innihalda þá og aðferðir til að nota þá IS6425A (is)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17134199P 1999-12-21 1999-12-21
US18733600P 2000-03-06 2000-03-06
US18791000P 2000-03-08 2000-03-08
US19060300P 2000-03-20 2000-03-20
PCT/US2000/035178 WO2001045692A1 (en) 1999-12-21 2000-12-21 Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them

Publications (1)

Publication Number Publication Date
IS6425A true IS6425A (is) 2002-06-18

Family

ID=27496950

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6425A IS6425A (is) 1999-12-21 2002-06-18 Nýir sertralínhýdróklóríð fjölgervingar, aðferðirtil að búa þá til, blöndur sem innihalda þá og aðferðir til að nota þá

Country Status (19)

Country Link
US (2) US6452054B2 (is)
EP (2) EP1797875A3 (is)
JP (2) JP4057295B2 (is)
KR (1) KR100791872B1 (is)
CN (1) CN1434708A (is)
AT (1) ATE354358T1 (is)
AU (1) AU780771B2 (is)
DE (1) DE60033566T2 (is)
DK (1) DK1248605T3 (is)
ES (1) ES2281374T3 (is)
HR (1) HRP20020543A2 (is)
HU (1) HUP0204010A3 (is)
IL (1) IL150332A0 (is)
IS (1) IS6425A (is)
PL (1) PL356452A1 (is)
PT (1) PT1248605E (is)
SK (1) SK8872002A3 (is)
WO (1) WO2001045692A1 (is)
YU (1) YU47902A (is)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5845313A (en) 1995-07-31 1998-12-01 Lexar Direct logical block addressing flash memory mass storage architecture
US6978342B1 (en) 1995-07-31 2005-12-20 Lexar Media, Inc. Moving sectors within a block of information in a flash memory mass storage architecture
US6500987B1 (en) * 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
US6495721B1 (en) 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
TWI260315B (en) 1999-10-29 2006-08-21 Ciba Sc Holding Ag Polymorphic forms of sertraline hydrochloride
EP1797875A3 (en) * 1999-12-21 2007-08-29 Teva Pharmaceutical Industries Ltd Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them
KR20070002101A (ko) * 2000-03-14 2007-01-04 테바 파마슈티컬 인더스트리즈 리미티드 (+)-시스-세르트랄린의 신규한 제조 방법
CA2448279A1 (en) * 2001-05-31 2002-12-05 Orion Corporation Fermion Process for preparing sertraline hydrochloride polymorphic form ii
CA2448300A1 (en) * 2001-05-31 2002-12-05 Orion Corporation Fermion Process for preparing sertraline intermediates
GB0123421D0 (en) 2001-09-28 2001-11-21 Memquest Ltd Power management system
AU2003251290A1 (en) * 2002-04-29 2003-11-17 Teva Pharmaceutical Industries Ltd. Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20040131672A1 (en) * 2003-01-07 2004-07-08 Nilobon Podhipleux Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties
WO2005000786A1 (en) * 2003-05-23 2005-01-06 Transform Pharmaceuticals, Inc. Sertraline compositions
CA2537804A1 (en) * 2003-09-05 2005-03-17 Teva Pharmaceutical Industries Ltd A recycling process for preparing sertraline
KR101161813B1 (ko) * 2003-11-04 2012-07-05 씨아이피엘에이 엘티디. 선택적인 세로토닌 재흡수 억제제의 다형체들의 제조 방법
US7464306B1 (en) 2004-08-27 2008-12-09 Lexar Media, Inc. Status of overall health of nonvolatile memory
TW200640836A (en) * 2005-02-23 2006-12-01 Teva Pharma Processes for preparing sertraline
WO2006103506A1 (en) * 2005-03-31 2006-10-05 Ranbaxy Laboratories Limited Sertraline-containing pharmaceutical compositions and a process for preparation thereof
GB0507090D0 (en) * 2005-04-07 2005-05-11 Sandoz Ag Process for preparing polymorphic form ll of sertraline hydrochloride
US7518019B2 (en) * 2006-06-01 2009-04-14 Hetero Drugs Limited Processes for preparing sertraline hydrochloride crystalline forms
US20060257475A1 (en) * 2006-08-17 2006-11-16 Boehringer Ingelheim International Gmbh Stable Sertraline Hydrochloride Formulation and Method
CA2594198A1 (en) * 2007-07-20 2009-01-20 Apotex Pharmachem Inc. A novel process for the preparation of sertraline hydrochloride form ii
FR2928148B1 (fr) * 2008-02-28 2013-01-18 Sanofi Aventis Procede de preparation de combretastatine
EP3578546A1 (en) 2013-11-15 2019-12-11 Akebia Therapeutics Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US5082970A (en) 1991-03-06 1992-01-21 Pfizer Inc. Process for recycling amine isomer
GB9114947D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5734083A (en) * 1996-05-17 1998-03-31 Torcan Chemical Ltd. Sertraline polymorph
CN1216033C (zh) 1998-03-18 2005-08-24 西巴特殊化学品控股有限公司 亚环己基胺的顺式选择性催化氢化方法
JP2000026379A (ja) * 1998-07-08 2000-01-25 Sumika Fine Chemicals Co Ltd 塩酸セルトラリンメタノール和物および塩酸セルトラリンエタノール和物、ならびにそれらの製法
US6500987B1 (en) * 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
IL143311A0 (en) * 1998-11-27 2002-04-21 Teva Pharma Sertraline hydrochloride polymorphs
US6495721B1 (en) 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
TWI260315B (en) * 1999-10-29 2006-08-21 Ciba Sc Holding Ag Polymorphic forms of sertraline hydrochloride
EP1797875A3 (en) * 1999-12-21 2007-08-29 Teva Pharmaceutical Industries Ltd Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them
IN192343B (is) 2000-05-26 2004-04-10 Ranbaxy Lab Ltd

Also Published As

Publication number Publication date
US6452054B2 (en) 2002-09-17
ATE354358T1 (de) 2007-03-15
HUP0204010A3 (en) 2006-02-28
EP1248605A2 (en) 2002-10-16
SK8872002A3 (en) 2002-12-03
EP1248605A4 (en) 2004-11-24
EP1248605B1 (en) 2007-02-21
ES2281374T3 (es) 2007-10-01
JP4057295B2 (ja) 2008-03-05
EP1797875A3 (en) 2007-08-29
AU780771B2 (en) 2005-04-14
WO2001045692A9 (en) 2002-07-04
JP2003518056A (ja) 2003-06-03
IL150332A0 (en) 2002-12-01
EP1797875A2 (en) 2007-06-20
DE60033566T2 (de) 2007-10-25
US6858652B2 (en) 2005-02-22
US20010041815A1 (en) 2001-11-15
KR100791872B1 (ko) 2008-01-07
HRP20020543A2 (en) 2005-04-30
PT1248605E (pt) 2007-03-30
US20030023117A1 (en) 2003-01-30
WO2001045692A1 (en) 2001-06-28
DK1248605T3 (da) 2007-03-19
HUP0204010A2 (hu) 2003-04-28
CN1434708A (zh) 2003-08-06
JP2007308505A (ja) 2007-11-29
PL356452A1 (en) 2004-06-28
YU47902A (sh) 2005-11-28
DE60033566D1 (de) 2007-04-05
AU2737601A (en) 2001-07-03
KR20020062356A (ko) 2002-07-25

Similar Documents

Publication Publication Date Title
IL150332A0 (en) Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them
ES2164842T3 (es) Procedimiento para la preparacion de composiciones de microcapsulas.
UY26130A1 (es) Compuestos para tratar la obesidad
NO20030845D0 (no) Utvalgte fusjonerte pyrrolokarbazoler
BR0113286A (pt) Pirazóis substituìdos
BR0313265A (pt) Compostos e respectivos processos de preparação, uso e formulações farmacêuticas e métodos de prevenção e/ou tratamento de distúrbios mediados por receptor mglur5 e de inbição da ativação de receptores mglu r5.
ATE551340T1 (de) Azabicyclisch- substituierte annelierte heteroaryl-verbinungen für die behandlung von krankheiten
SV1998000153A (es) Proceso para la sintesis de 1,3-dioles
ATE334662T1 (de) Herstellungsverfahren von arzneizubereitungen
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
MXPA02011288A (es) Tioacetamidas substituidas.
ATE422498T1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
ATE329588T1 (de) Verwendung von sibutramin zur behandlung von von organischen störungen verursachten zns- erkrankungen
MXPA04003796A (es) Tioacetamidas sustituidas.
PT1414816E (pt) Polimorfo estavel da flibanserina, processo tecnico para a sua preparacao e sua utilizacao na preparacao de medicamentos
ATE355067T1 (de) 15-keto-prostaglandine zur behandlung arzneimittelinduzierter obstipation
BR0200249A (pt) Misturas de borracha contendo terpolìmeros
DE59914712D1 (de) Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden
BG101605A (bg) Ентерокинетични бензамиди
NO20023150D0 (no) Fremgangsmåte for fremstilling av citalopram
IS6087A (is) N-(2-fenýl-4-amínó-bútýl)-1-naftamíð sem virka á móti taugakínín-1 viðtaka
NO20031413D0 (no) Ny fremgangsmåte for fremstilling av oksabispidiner
BR0016942A (pt) Derivados substituìdos de aminometil-fenil-ciclohexano
TR200402230T4 (tr) O-ikameli 6-metil-tramadol-türevleri
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall